Holen Sie sich die Stockscreener-App
61.23
3.17%
1.88
Handel nachbörslich:
61.14
-0.09
-0.15%
Schlusskurs vom Vortag:
$59.35
Offen:
$59.43
24-Stunden-Volumen:
3.20M
Relative Volume:
1.39
Marktkapitalisierung:
$9.76B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-20.14
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+43.61%
1M Leistung:
+42.23%
6M Leistung:
+81.42%
1J Leistung:
+27.17%
1-Tages-Spanne:
$59.22
$62.01
1-Wochen-Bereich:
$49.13
$62.08
52-Wochen-Spanne:
$23.95
$62.08
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
61.23 | 9.46B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Does Ionis Pharmaceuticals Inc. stock have upside surprise potentialQuarterly Growth Report & Expert-Curated Trade Recommendations - خودرو بانک
What are analysts’ price targets for Ionis Pharmaceuticals Inc.2025 Key Lessons & Precise Buy Zone Tips - خودرو بانک
Ionis Pharma EVP Baroldi sells $1.95m in shares By Investing.com - Investing.com Australia
Ionis Pharmaceuticals director Wender sells $1.6m in shares By Investing.com - Investing.com South Africa
Is Ionis Pharmaceuticals Inc. a potential multi baggerJuly 2025 Price Swings & Long-Term Safe Return Strategies - خودرو بانک
What is the earnings history of Ionis Pharmaceuticals Inc.Quarterly Profit Report & Smart Swing Trading Techniques - خودرو بانک
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
How sentiment analysis helps forecast Ionis Pharmaceuticals Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Ionis Pharmaceuticals Stock (IONS) Opinions on Olezarsen Trial Results and FDA Approval - Quiver Quantitative
Ionis pharma EVP O’Neil sells $5.39 million in IONS stock - Investing.com Nigeria
Ionis Pharma EVP Schneider sells $1.19m in shares By Investing.com - Investing.com Nigeria
Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN
Market reaction to Ionis Pharmaceuticals Inc.’s recent newsTrade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 38% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Analyzing Ionis Pharmaceuticals Inc. with risk reward ratio charts2025 Stock Rankings & Expert Curated Trade Ideas - Newser
Assessing Insider Selling at Ionis Pharmaceuticals: Implications for Investor Confidence and Stock Valuation - AInvest
Ionis Pharmaceuticals Insider Sold Shares Worth $2,301,264, According to a Recent SEC Filing - MarketScreener
Ionis Pharmaceuticals Insider Sold Shares Worth $1,946,220, According to a Recent SEC Filing - MarketScreener
Insider Selling at Ionis Pharmaceuticals: A Signal or a Symptom? - AInvest
Real time breakdown of Ionis Pharmaceuticals Inc. stock performanceJuly 2025 Momentum & Low Risk High Reward Trade Ideas - Newser
Ionis Pharma director Klein sells $1.68 million in shares - Investing.com India
Ionis Pharma EVP Baroldi sells $1.95m in shares - Investing.com India
Ionis Pharmaceuticals director sells $1.6m in IONS stock By Investing.com - Investing.com Canada
Ionis pharma EVP Devers sells $192,942 in IONS stock By Investing.com - Investing.com Nigeria
Ionis Pharma EVP Schneider sells $1.19m in shares - Investing.com
SEC Filings Archive 2025-09-04Historical 10-K, 10-Q, 8-K Forms - Stock Titan
Ionis Pharma director Loscalzo sells $962k in shares - Investing.com
Ionis Pharmaceuticals director Klein sells $1.68 million in shares - Investing.com India
Ionis pharma EVP Devers sells $192,942 in IONS stock - Investing.com India
Insider Sell: Brett Monia Sells 203,814 Shares of Ionis Pharmace - GuruFocus
Ionis Pharmaceuticals director Wender sells $1.6m in shares - Investing.com
Ionis Pharmaceuticals CEO Monia sells $12.3 million in IONS stock - Investing.com India
Ionis Pharma EVP Geary sells $503,671 in IONS stock - Investing.com
Ionis Pharmaceuticals director sells $1.6m in IONS stock - Investing.com
How to use a screener to detect Ionis Pharmaceuticals Inc. breakoutsQuarterly Trade Review & Risk Controlled Daily Plans - Newser
Ionis Pharmaceuticals director Klein sells $1.68 million in shares By Investing.com - Investing.com UK
Ionis Pharmaceuticals CEO Monia sells $12.3 million in IONS stock By Investing.com - Investing.com UK
Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen - MSN
Ionis Falls 1.88% with 63% Volume Drop Ranking 457th as BMO Upgrades to 'Outperform' on Breakthrough Drug Outlook - AInvest
Ionis Pharmaceuticals’ Strategic Position in the Biotech Sector: Growth Potential in Therapeutic Innovation and Market Leadership - AInvest
What drives Ionis Pharmaceuticals Inc.’s stock price2025 Volume Leaders & Proven Capital Preservation Methods - خودرو بانک
Is Ionis Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & AI Based Trade Execution Alerts - خودرو بانک
RBC Capital Adjusts Price Target on Ionis Pharmaceuticals to $80 From $70, Maintains Outperform Rating - MarketScreener
Is Ionis Pharmaceuticals Inc. stock entering bullish territoryMarket Activity Report & AI Forecast for Swing Trade Picks - Newser
When is the best time to exit Ionis Pharmaceuticals Inc.July 2025 Momentum & Fast Entry High Yield Stock Tips - Newser
What’s next for Ionis Pharmaceuticals Inc. stock priceDollar Strength & Community Driven Trade Alerts - Newser
Ionis Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - Newser
Building trade automation scripts for Ionis Pharmaceuticals Inc.Market Volume Report & Real-Time Chart Breakout Alerts - Newser
Has Ionis Pharmaceuticals Inc. formed a bullish divergenceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Street Watch: Is Ionis Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Catalysts & Consistent Profit Trade Alerts - خودرو بانک
Ionis Pharmaceuticals Executives Buy Shares Amid Recent Market Volatility. - AInvest
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):